Pathogenesis of sporadic inclusion body myositis: Significance of inflammation and implications for therapeutic strategies;Pathogenese der einschlusskörperchenmyositis: Stellenwert der entzündung und bedeutung für therapiestrategien

Aktuelle Neurologie

Volumn 36, Issue 3, 2009, Pages 121-125

  Schmidt, Jens ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Autoimmunity; Myopathy; Myositis

Indexed keywords

ALEMTUZUMAB; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AZATHIOPRINE; BETA SECRETASE; CXCL9 CHEMOKINE; CYCLOSPORIN; INTERLEUKIN 1BETA; METHOTREXATE; OXANDROLONE; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ANTIGEN PRESENTATION; AUTOPHAGY; CYTOTOXIC T LYMPHOCYTE; HUMAN; INCLUSION BODY MYOSITIS; MUSCLE CELL; PATHOGENESIS; REVIEW;

EID: 67649442680     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0028-1090214     Document Type: Review

References (38)

1. Needham M, Corbett A, Day T et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15: 1350-1353
2. Dalakas MC. Sporadic inclusion bodymyositis - diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2: 437-447 (Pubitemid 44137945)
3. Askanas V, Engel WK. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008; 116: 583-595
4. Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006; 2: 219-227
5. Askanas V, Engel WK. Inclusion-bodymyositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007; 19: 550-559 (Pubitemid 47530874)
6. Kumamoto T, Ueyama H, Tsumura H et al. Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis. Acta Neuropathol 2004; 107: 59-65 (Pubitemid 38088276)
7. Ventruti A, Cuervo AM. Autophagy and neurodegeneration. Curr Neurol Neurosci Rep 2007; 7: 443-451 (Pubitemid 47422787)
8. Lunemann JD, Schmidt J, Schmid D et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007; 61: 476-483 (Pubitemid 46878775)
9. Maiuri MC, Zalckvar E, Kimchi A et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752 (Pubitemid 47312826)
10. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-380 (Pubitemid 40835843)
11. Bradshaw EM, Orihuela A, McArdel SL et al. A local antigen-driven humoral response is present in the inflammatorymyopathies. J Immunol 2007; 178: 547-556 (Pubitemid 46033639)
12. Greenberg SA, Bradshaw EM, Pinkus JL et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65: 1782-1787 (Pubitemid 43754412)
13. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342-347 (Pubitemid 26085583)
14. De Paepe B, Creus KK, De Bleecker JL. Chemokines in idiopathic inflammatory myopathies. Front Biosci 2008; 13: 2548-2577 (Pubitemid 351599704)
15. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-231 (Pubitemid 19081957)
16. Behrens L, Kerschensteiner M, Misgeld T et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998; 161: 5943-5951 (Pubitemid 28535962)
17. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548 (Pubitemid 40563179)
18. Wiendl H, Mitsdoerffer M, Schneider D et al. Muscle fibres and cultured muscle cells express the B7.1/ 2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126: 1026-1035
19. Schmidt J, Rakocevic G, Raju R et al. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8(+) T cell cytotoxicity. Brain 2004; 127: 1182-1190 (Pubitemid 38623051)
20. Goebels N, Michaelis D, Engelhardt M et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermato- myositis. J Clin Invest 1996; 97: 2905-2910 (Pubitemid 26197106)
21. Hohlfeld R, Engel AG. Coculture with autologousmyotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29: 498-507
22. Waschbisch A, Wintterle S, Lochmuller H et al. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum 2008; 58: 3600-3608
23. Wiendl H, Mitsdoerffer M, Schneider D et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003; 17: 1892-1894
24. Schmidt J, Barthel K, Wrede A et al. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-1240
25. Nagaraju K, Raben N, Merritt G et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407-414 (Pubitemid 28410566)
26. Vattemi G, Engel WK, McFerrin J et al. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 2001; 358: 1962-1964 (Pubitemid 34072880)
27. Hong HS, Hwang EM, Sim HJ et al. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003; 307: 922-927 (Pubitemid 36871661)
28. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008; 64: 15-24
29. Griggs RC. The current status of treatment for inclusion-body myositis. Neurology 2006; 66: S30-S32 (Pubitemid 43739981)
30. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63: 718-720 (Pubitemid 39100834)
31. Dalakas MC, Sonies B, Dambrosia J et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-716 (Pubitemid 27120112)
32. Walter MC, Lochmuller H, Toepfer M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247: 22-28 (Pubitemid 30162508)
33. van der Pas J, Hengstman GJD, ter Laak HJ et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75: 136-139 (Pubitemid 38091283)
34. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-424
35. Lindberg C, Trysberg E, Tarkowski A et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61: 260-262 (Pubitemid 36875317)
36. Dalakas MC, Rakocevic G, McElroy B et al. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion bodymyositis (sIBM) alters disease progression and suppresses endomysial inflammation. Ann Neurol 2007; 62: S60-S61
37. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69: 2008-2019 (Pubitemid 350145093)
38. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4: 557-567